Open AccessNoncoding RNA s as therapeutic targets in atherosclerosis with diabetes mellitus
Author(s) -
Tang Ningning,
Jiang Shaoyan,
Yang Yanyan,
Liu Shaoyan,
Ponnusamy Murugavel,
Xin Hui,
Yu Tao
Publication year - 2018
Publication title -
cardiovascular therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.818
H-Index - 46
eISSN - 1755-5922
pISSN - 1755-5914
DOI - 10.1111/1755-5922.12436
Subject(s) - medicine , diabetes mellitus , pathological , bioinformatics , disease , vascular smooth muscle , clinical trial , therapeutic approach , animal studies , smooth muscle , endocrinology , biology
Summary Atherosclerosis is one of the major macrovascular complications of diabetes mellitus ( DM ), and it is the main cause of death from clinical observation. Among various cell types involved in this disorder, endothelial cells, vascular smooth muscle cells ( VSMC s), and macrophages play a crucial role in the occurrence and development of this disease. The regulation and stabilization of these cells are a key therapeutic strategy for DM ‐associated atherosclerosis. An increasing number of evidences implicate that various types of noncoding RNA s (nc RNA s) play a vital role in many cellular responses as well as in physiological and pathological processes of atherosclerosis and DM that drive atherogenic/antiatherogenic processes in those cells. Encouragingly, many nc RNA s have already been tested in animal experiments or clinical trials showing good performance. In this review, we summarize recent progresses in research on functional regulatory role of nc RNA s in atherosclerosis with DM . More importantly, we illustrate new thoughts and findings relevant to nc RNA s as potential therapeutic targets or biomarkers for atherosclerosis with DM .